Large-scale sequencing studies of patient cohorts enable identification of many cancer driver genes. However, not every mutation in a driver gene is necessarily a driver of cancer; thus requiring methods to discriminate whether an individual mutation is a driver or passenger. By completely re-working the CHASM algorithm, CHASMplus leverages multi-scale context to identify driver missense mutations, and consistently outperforms comparable methods across a wide variety of benchmarks -including in vitro experiments, in vivo experiments, and literature curation. Applied to 8,657 samples across 32 cancer types, CHASMplus identifies 3,527 unique driver mutations. Our results support a prominent emerging role for rare driver mutations. To our knowledge, this study is the first to systematically assess variability across cancer types with respect to the spectrum of common, intermediate, and rare frequency driver mutations. We show that the trajectory of driver discovery is systematically different across cancer types, depending on mutational prevalence and diversity.
Introduction
While somatic missense mutations are the most common protein-coding mutations in human cancers, their impact on cancer cell fitness is highly variable. Missense mutations may be critical to increasing the net growth of a cancer cell in vivo (drivers), while others are benign passengers 1 . Certain cancer types are known to be driven by well-established, highly prevalent missense mutations in oncogenes, such as KRAS G12 mutations in pancreatic ductal adenocarcinoma 2 or IDH1 R132 mutations in glioblastoma multiforme 3 . The OncoKB database 4 , a literature curated knowledgebase, has compiled a list of approximately two thousand driver missense mutations. This database is likely incomplete because of the current limited throughput of functional validation assays for driver missense mutations. It has been hypothesized that cancer driver mutations exhibit a long tail phenomenon with few common drivers and many rare drivers 5, 6 , suggesting that numerous rare drivers remain to be discovered.
Outstanding questions remain about the spectrum of driver missense mutations, their cancer type specificity, and their potential clinical relevance.
. The task of identifying drivers from cancer sequencing studies has classically used statistical models that identify an excess number of mutations over expectation 7, 8 . However, most genes are large and even within a driver gene numerous passenger mutations are expected to accumulate 9 . This leads to uncertainty on whether an individual mutation is a driver.
Approaches to improve the specificity of driver discovery have focused on smaller intra-genic regions, such as protein domains 10 , protein-protein interfaces 11, 12 , and individual codons 13 .
An alternative approach is to apply machine learning to predict the cancer driver status of individual missense mutations by leveraging features characterizing the mutation, e.g., interspecies evolutionary conservation, features of the local protein environment, molecular function annotations, and biophysical characterizations of the amino acid substitution. Cancer-focused machine learning methods have previously tried to enhance performance by training cancer type specific models 14, 15 or boosting data with synthetic passenger missense mutations 14 .
While results have been promising, a recent systematic study comparing 15 such methods concluded that none of them were yet sufficiently reliable to guide high-cost experimental or clinical follow-through 16 . We and others have hypothesized that determining the impact of missense mutations requires proper context 17 , which has not yet been systematically leveraged in the current generation of methods. Context includes both prior knowledge about the functional importance of genes or gene subregions in which a mutation occurs, and mutational patterns that are now evident from cancer sequencing studies of many thousands of patients.
In this work, we present a new driver missense mutation prediction method, CHASMplus, that uses machine learning to integrate missense mutation context at multiple scales. The new CHASMplus consistently outperforms comparable methods, including the original CHASM, on eight different benchmark sets --including in vitro experiments, in vivo experiments and literature benchmarks. Encouraged by these results, we applied CHASMplus to 8,657 The
Cancer Genome Atlas (TCGA) samples from 32 cancer types to systematically identify driver missense mutations. The resulting predictions support a high degree of variability in the contributions of rare, intermediate, and common driver missense mutations across cancer types. The prevalence and diversity of the driver mutation landscape differ by cancer type, suggesting which cancer types are saturated for driver discovery and those most likely to benefit by additional sequencing studies.
Result

Overview of CHASMplus
CHASMplus uses the Random Forest algorithm to discriminate somatic missense mutations (referred to hereafter as missense mutations) as either cancer drivers or passengers (Online Methods). A Random Forest is an ensemble of many randomized decision trees 18, 19 . Each tree is trained on a random selection of training set examples and candidate features, via a recursive splitting process 20 ( Fig 1a) . CHASMplus is trained using somatic mutation calls from The Cancer
Genome Atlas (TCGA) covering 8,657 samples in 32 cancer types (Table S1 , Online Methods).
Because there is no gold standard set of driver and passenger missense mutations, we developed a semi-supervised approach to assign class labels to missense mutations, taking advantage of Random Forest robustness to noisy class labels. Briefly, class labels are assigned so as to enrich the positive class for driver missense mutations (Online Methods, Fig   S1) . CHASMplus training is done with a rigorous gene holdout cross-validation protocol to avoid overfitting, by ensuring all mutations within a gene are within the same fold 21 . Therefore, missense mutations are never scored by a Random Forest trained on any missense mutation harbored by the same gene. Finally, predicted scores from CHASMplus are weighted by the 20/20+ driver gene score, producing gene-weighted (gwCHASMplus) scores (Fig 1b, Online Methods).
CHASMplus scores benefit from representation of missense mutation context at multiple scales.
The Random Forest was trained on 95 features (Table S2) ... ...
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CHASMplus dramatically improves identification of somatic missense mutation drivers
We next sought to compare the performance of CHASMplus with respect to 12 comparable methods by using seven mutation-level benchmarks. Our benchmarks fall under three broad categories: in vitro experiments, high throughput in vivo screens, and curation from published literature. Each of these categories has weaknesses, but, in aggregate, they span multiple scales of evaluation and amount of supportive evidence (Fig 2a) . For example, several benchmarks are limited to one or a few well-established driver genes, while others are exomewide, but lack experimental support. A range of benchmarks is critical because missense mutations with the most established experimental support for a driver role tend to be in a few well-understood cancer driver genes. However, limiting benchmarking to these genes makes it difficult to assess the generalizability of a method's performance to missense mutations in other genes. All benchmark evaluations used the area under the Receiver Operating Characteristic Curve (auROC) as a metric (Fig 2b, Fig S2 , Table S3 ). Overall, CHASMplus had a mean auROC of 0.09 higher than the next best method. This common metric is used in machine learning to describe how well predictions separate two classes without a priori selecting a score threshold, which for many methods is not well defined 25 . In our assessment, the two classes represent likely driver and passenger missense mutations. In general, auROC values range from 0.5 (random prediction performance) to 1.0 (perfect). Table S1 .
We used three benchmarks based on in vitro experiments (Online Methods). The first was a set of missense mutations assessed by an assay of cell viability in two growth-factor dependent cell CHASMplus significantly outperformed all other methods, the nearest being ParsSNP (p=7e-14, delong test).
CHASMplus improves identification of cancer type specific driver genes
We evaluated the performance of CHASMplus on identifying cancer-type specific driver genes, using a previously published benchmark and assessment of 15 computational methods designed for this purpose 31 . Genes were labeled by their designations in the Cancer Gene
Census as a cancer driver gene for a specific cancer type. Out of the 4 cancer type cohorts assessed (BLCA, BRCA, GBM, and LUAD), CHASMplus had the highest average F1 score, a balance between precision and recall that was used as a performance metric by 31 (Fig 2c) . We additionally note that of the methods tested, CHASMplus was the only one not primarily designed to predict driver genes that had high recall (average recall=.45) while maintaining precision (average precision=.23) (Fig S3) .
CHASMplus identifies both common and rare cancer drivers
Certain cancer driver mutations primarily occur in a specific cancer type, while others appear in many cancer types. The power to detect driver mutations, which occur at low frequency in many cancer types, is increased when many cancer types are aggregated, known as a pancancer analysis. Conversely, driver mutations, which are specific to a particular cancer type, are best identified when cancer types are analyzed individually 32 . Using CHASMplus, we identified 3,527 unique missense mutations as statistically significant drivers by pan-cancer analysis at an estimated false discovery rate of 1% (Table S4 ). When applied to each cancer type individually, the number found significant varied substantially from 8 in thymoma to 572 in bladder urothelial carcinoma with a median of 78 (Fig 3a, Table S5 ). The median overlap with literature-based oncogenicity annotation from OncoKB was 53%, suggesting 47% of the driver missense mutations identified by CHASMplus either have not been previously characterized or not sufficiently characterized for inclusion in OncoKB. While OncoKB missense mutation annotations are not cancer-type specific, the genes with highest frequencies of cancer-type specific driver missense mutations identified by CHASMplus have well-known roles in cancer 33 ( Fig 3b) . Table S1 .
The long tail hypothesis, initially proposed from examining overall mutation frequency of driver genes 5, 6 , suggests there are few common drivers and many rare drivers. However, the overall mutation frequency of a gene does not account for the confounding presence of passenger mutations within a driver gene. From our mutation-level analysis, we observed that the spectrum of rare (<1% of cancer samples), intermediate (1-5%), and common (>5%) driver missense mutations varied substantially among cancer types (Fig 3c) . For example, uveal melanoma was dominated by common driver missense mutations (88%), while head and neck squamous cell carcinoma (HNSC) was dominated by rare driver missense mutations (63%). Interestingly, from the pan-cancer analysis, the overall proportion of driver missense mutations considered rare was only slightly smaller than for common drivers (35.4% and 35.5%, respectively), but 4-fold greater than found by a previous method (8%, P<2.2e-16, Fisher's exact test) 13 . , contained common driver missense mutations in our pan-cancer analysis at residue positions 179 and 183, which is located at the protein interface composing the phosphatase 2A complex (Fig 3d) . It also had a much broader set of rare drivers throughout the protein interface, such as R105Q and R459C. Similarly, CHASMplus identified common driver missense mutations (S310A/F/Y) in the extracellular domain of the well-known oncogene ERBB2, but also finds rare driver missense mutations in both the extracellular and kinase domain (e.g., L313V
and R678Q) (Fig 3e) . This is supportive of previous experimental work implicating rare cancer driver mutations in common cancer driver genes 29 .
Mutation hotspot detection approaches have limited power
A codon or small region of protein sequence or structure where recurrent mutations are observed is known as a hotspot. Similar to statistical methods for driver gene detection, hotspot detection identifies an excess number of mutations compared to expectation using a large number of cancer samples. We asked whether, given current cohort sizes, codon-based hotspot detection had sufficient statistical power to identify rare driver mutations. We assessed the number of samples required to detect driver mutations across a range of frequencies (proportion of samples in which a mutation occurs) and somatic background mutation rates. In Table S1 . At current TCGA sample sizes, we found codon-based hotspot detection approaches were not well powered to identify driver mutations that occurred at less than 1% frequency in most cancer types. Exceptions were thyroid carcinoma (THCA), low grade glioma (LGG) and breast cancer (BRCA), which are seen to lie above (or close to) the curve representing 1% frequency (Fig 4a) .
Notably, these cohorts had large numbers of samples and low-to-medium background mutation rates. We also found that when cancer types were aggregated in pan-cancer analysis, power to detect codon-based hotspots improved substantially, but only when the recurrent mutations were shared in more than one cancer type. For these mutations, pan-cancer analysis using ~10,000 TCGA samples should enable detection of driver mutations at frequency as low as 0.1%.
In our pan-cancer analysis, CHASMplus had greater sensitivity to detect putatively oncogenic missense mutations than a recently published codon-based hotspot detection method. We compared the missense mutations in the TCGA pan-cancer cohort that were called statistically significant by CHASMplus and those called by a hotspot method described by 13 (Fig 4b) .
Moreover, these results are also reflected in the number of significant predictions of the two methods. The codon-based hotspot method only identified 360 unique codons as significant in our TCGA data set, while CHASMplus found significant missense mutations in 2,588 codons.
We believe that the increased sensitivity is the result of CHASMplus using a broad range of important features, including multi-resolution hotspot detection and weighting by driver gene scores (Fig 1c) . Importantly, our increased sensitivity did not come at the cost of low specificity, as evidenced by our p-value calibration (Fig S1c) and extensive ROC analysis across seven benchmarked datasets (Fig 2b) , which measures a balance of sensitivity and specificity.
Characterizing cancer types and the trajectory of discovery
The diversity and prevalence of driver missense mutations varied considerably across TCGA cancer types (Fig 4c, Online Methods) . We defined diversity with respect to the distribution of driver missense mutations across codons and prevalence with respect to the frequency of the mutations in tumor samples. High diversity indicated mutations were broadly distributed across codons, while high prevalence indicated driver missense mutations that occurred in a large number of tumor samples. Using K-means clustering, we found that cancer types grouped into high diversity and low prevalence (12 cancer types), high diversity and high prevalence (15 cancer types), and low diversity and high prevalence (5 cancer types). These differences were not associated with intra-tumor heterogeneity or normal contamination, as assessed by mean variant allele fraction (VAF) of a cancer type (p>0.05, correlation test). The differences also could not be associated only with TCGA sample size for a particular cancer type. For example, while both pancreatic ductal adenocarcinoma (PAAD) and sarcoma (SARC) had similar sample sizes (n=155, n=204 respectively), PAAD had high prevalence and low diversity, while SARC had low prevalence and high diversity. After adjusting for sample size, we observed that the average mutation burden for a cancer type positively correlated with the prevalence of rare (but not common) driver missense mutations (R=0.63, P=4.7e-5, likelihood ratio test).
Are there substantially more cancer driver missense mutations yet to be discovered? If discovery was measured by the number of unique driver missense mutations identified, subsampling analysis showed all cancer types had a linear increase ( " > 0.5) with no evidence of saturation at current sample sizes (Fig S5) . However, we observed substantial variability in trajectories if discovery was measured by driver prevalence (average number of driver missense mutations per cancer sample) (Fig 4d) , a metric which goes directly to utility of driver discovery in clinical practice (Discussion). For sarcoma (SARC), adrenocortical carcinoma (ACC), and prostate adenocarcinoma (PRAD), driver prevalence remained minimal as sample size increased. As a case in point, we repeated our analysis on data from a recently released PRAD study 35 , which augmented the 477 TCGA PRAD samples with 536 additional samples. This resulted in only marginal increases in the overall prevalence of identified driver missense mutations, consistent with our predicted trajectory based only on TCGA samples (Supplementary Materials and Methods, Table S6 , Fig S6) . In contrast, thymoma (THYM), uveal melanoma (UVM), and pancreatic ductal adenocarcinoma (PAAD) contained common driver missense mutations that could be detected by using only a few samples from the cohort, e.g., GTF2I L424H in THYM. Due to a lack of rare or intermediate driver missense mutations, we observed THYM and UVM saturated discovery as sample size increased. Although PAAD showed a growing set of intermediate/rare driver missense mutations, the overall driver prevalence exhibited a diminishing rate of discovery. In contrast, breast (BRCA), head and neck squamous (HNSC), and colon cancers (COAD) harbored a full spectrum of driver missense mutations, with rare drivers increasing substantially as a function of sample size.
Discussion
Cancer genome interpretation is challenged by the reality that of all somatic mutations observed in cancer, only a small proportion are drivers 36 . Future insights into cancer evolution and its relevance for clinical care will increasingly rely on the precise interpretation of whether individual mutations are cancer drivers 37 . While many computational methods have been developed for this purpose, evaluations by external groups suggest that improvements are needed 16, 38 . In this work, we used a large dataset (~9,000 cancer samples) from The Cancer Genome Atlas Although not perfect, we believe the application of multiple independent benchmarks spanning a wide array of genes is the current best practice for demonstrating effectiveness.
The long tail hypothesis 5, 6 posits that there are many rare driver mutations in human cancers.
Insight into rare driver mutations has been limited by the lack of statistical power from traditional hotspot detection approaches. To overcome this limitation, we leveraged the improvements made in CHASMplus to systematically predict driver missense mutations in 8,657 samples from the TCGA. Although individually rare, we found a prominent emerging role for rare driver missense mutations in aggregate, consistent with the long tail hypothesis. This result supports the critical role of understanding the prevalence of driver mutations --failure to capture and identify rare driver mutations, which occur in aggregate at reasonable prevalence, may result in crucial missed opportunities for interpreting a patient's cancer. Because high-throughput functional validation studies of missense mutations are not yet widespread, computational methods, like CHASMplus, are needed to prioritize mutations for low-and medium-throughput studies. A benefit of CHASMplus is that we have precomputed a score for every possible missense mutation, forming an in silico saturation mutagenesis across all genes to score as of yet unobserved mutations that are potential cancer drivers. We provide scores for each of the 32 TCGA cancer types, as well as pan-cancer scores (available on request from the authors).
To our knowledge, ours is the first study to systematically show that the prevalence and diversity of driver missense mutations is highly variable across the cancer types represented in the TCGA. We observed that mutation burden for a cancer type positively correlated with prevalence of rare (but not common) driver missense mutations, even after correcting for sample size, suggesting that accumulating a greater number of mutations in a cancer may increase the competitiveness of rare drivers. More research into the origins of rare driver mutations is warranted, because differences in the rarity of driver missense mutations could arise from a variety of factors, including the driver's strength, dependence on genetic or environmental factors, competition from other types of tumor-derived alterations, or role in cancer subtypes.
We expect that an increasingly complete catalog of driver missense mutations will be generated by a combination improved computational methods and cumulative growth of available samples from cancer sequencing studies. The multi-faceted features used in CHASMplus yield an improvement in statistical power to effectively identify these mutations. However, for some cancer types, discovery may already be effectively saturated. We observed that the rate of new driver discoveries with greater sample size may decay because of the rarity of newly identified driver missense mutations; indicating the trajectory of driver discovery is more complicated than previously envisioned by an analysis of driver genes 35, 39 . The distinction of predicting drivers at the mutation-level is important, otherwise estimates will increasingly be inflated by the relatively greater proportion of passenger mutations within rare driver genes. Future work will further elucidate a broader range of driver mutations, including those within non-coding regions of the genome, and at different stages of carcinogenesis, such as in pre-cancerous lesions.
Online Methods
TCGA Mutation dataset
We collected a set of 1,225,917 somatic mutations in 8,657 samples from The Cancer Genome Atlas (TCGA) somatic mutation calls (v0.2.8, https://synapse.org/MC3) 40 . We analyzed 32
cancer types with abbreviations for the cancer types are listed in Table S1 . We further filtered mutations by restricting to only mutations with an annotated 'PASS' filter, except for OV and LAML where mutations with only whole genome amplified ('wga') status was allowed because otherwise the majority of samples were filtered. We additionally removed hypermutated samples, as they tend to have an adverse effect on statistical power. We identified hypermutated samples as having more mutations than 1.5 times the interquartile range above the third quartile (Tukey's condition) of samples within the same cancer type. Because some relatively low mutation rate cancer types contained outliers, we additionally required the sample to have at least 1,000 mutations to be considered hypermutated.
CHASMplus
The code for CHASMplus is available on github (https://github.com/KarchinLab/CHASMplus).
Features
CHASMplus uses features spanning somatic mutation hotspot detection, evolutionary conservation, genetic variation, molecular features, sequence-based features, amino acid substitution scores, and other covariates (Table S2) 
Training Set
Using the TCGA mutation dataset, we established training labels with a semi-supervised approach, designed to minimize bias. The positive class (likely-driver missense mutations) was selected by the following criteria: 1) missense mutations had to occur in a curated set of 125 pan-cancer driver genes 42 ; 2) for each of the 32 TCGA cancer types, missense mutations found in that cancer type had to occur in a significantly mutated gene for that cancer type according to MutSigCV v1.4 39 . We ran MutSigCV using recommended settings and a full sequencing coverage file (http://archive.broadinstitute.org/cancer/cga/mutsig). Importantly, MutSigCV v1.4
only assess the total number of mutations in a gene, and not any characteristics of those mutations; thus, we avoid making strong assumptions about the properties of a particular driver mutation; 3) missense mutations had to occur in samples with relatively low mutation rate (less than 500 mutations, half the minimum hypermutator threshold as defined above). This filter was intended to limit the number of passenger mutations mislabeled as drivers. The negative class (likely-passenger missense mutations) consisted of the remaining missense mutations in the TCGA mutation set. For training purposes, we only used unique mutations to avoid double counting a mutation seen more than once. If, however, the same mutation consequence observed in different cancer types had contradictory labels, we regarded the mutation as a driver because mutation recurrence is often cited as supportive evidence for a cancer driver
role. This established a set of 2,051 likely-driver missense mutations and 623,996 likelypassenger missense mutations, for which we found sufficient annotation to compute our were carried out as previously described 43 . We used all somatic mutations from the TCGA data to train a pan-cancer model. Driver gene scores for each cancer type or pan-cancer were then computed based on predictions from the trained model. The driver gene score represents the fraction of decision trees predicting driver for a particular gene in the random forest.
Random forest algorithm
We used random forests 18, 19 , a machine learning technique, to predict whether a missense mutation is a cancer driver. We trained a random forest using the randomForest R package. To ameliorate the problematic imbalance in the training set, we used a stratified down sampling approach within the bagging procedure of the random forest. Random undersampling has been previously recommended for random forests based on empirical performance 44 . The imbalance occurred on two levels, there were substantially more labeled passenger missense mutations than drivers, and among drivers it was concentrated in a few genes. We first calculated the median number of labeled driver missense mutations within genes containing at least one driver missense mutation label. If a gene contained more labeled driver missense mutations than the median, we set the number of driver missense mutations sampled from that gene to the median.
Passenger missense mutations were sampled at an equal frequency as driver missense mutations after the gene-based median correction.
Since CHASMplus and gwCHASMplus scores for all simulations were used as an empirical null distribution. To compute a P value for a score, we used the fraction of simulated mutations with a score equal to or greater than the actual score. P values were adjusted by the BenjaminiHochberg method for multiple hypotheses. We considered a missense mutation to be significant at a q-value threshold of 0.01.
Feature importance
We used the Mean Decrease in Gini Index (MDGI) as a measure of feature importance in the random forest. This measurement, however, has been previously noted to favor continuous features over discrete features with a small number of possible values 45 . We compensated for this phenomenon by calculating an adjusted z-score using a permutation-based approach. This involved calculating MDGI for each feature for 1,000 permutations and calculating the z-score of the observed data by using the mean and standard deviation of the permutations. The permutations were carried out as follows: First, we randomly permuted the list of unique genes containing any missense mutation. Second, we assigned the first gene in the permuted list with the same fraction of driver/passenger mutations as our first gene containing labeled driver mutations in our training set. We then proceeded to the next gene in the list, and repeated the procedure, until the same number of labeled driver mutations as in our actual training set was reached. All other genes had their mutations labeled as passengers. Finally, we computed the MDGI for each feature based on the CHASMplus model on the permuted training data.
Grouping by gene in the permutation was done to mimic the heuristic on how training data was labeled, and to avoid gene-level features from having artificially high feature importance.
Compared methods
We plus, we used the "cancer-in-general" scores, but this was not available for version 1.0, so instead we used the ovarian scores. CHASM was executed using a 10-fold gene-holdout crossvalidation procedure also using an ovarian passenger distribution. We executed ParsSNP using the provided pre-computed model where the input score annotations were obtained from ANNOVAR. FATHMM cancer scores were obtained directly from the available website (http://fathmm.biocompute.org.uk/). Inputs to each of the methods were prepared using custom python scripts.
CHASMplus was also compared to a codon-based hotspot method (v0.6) 13 , with respect to its ability to identify cancer type-specific driver genes, sensitivity at discovering oncogenic codons, and its calibration of p-values. The hotspot method was run using default parameters on the TCGA mutation dataset. For each gene, we used the biomart R package to measure its protein 
Driver mutation benchmarks
In each benchmark, we define a 'positive' (more driver-like) and 'negative' (more passengerlike) class for mutations to evaluate discriminating performance. We define the annotation of class and mutation data used for each benchmark below. Only missense mutations were used for each of the benchmarks. For reproducibility, all data, results, and analysis code are available on github (https://github.com/KarchinLab/Tokheim_biorxiv_2018).
CGC-recurrent
We examined driver prioritization on an exome-scale for our TCGA mutation dataset (see above) through a combined literature/heuristic evaluation. We first obtained a set of curated likely driver genes from the Cancer Gene Census (CGC, COSMIC v79) 33 . We restricted to only CGC genes that were labeled as somatic and marked as relevant for missense mutations. We Multiplexed xenograft tumorigenesis assay and In vitro EGFR resistance
Berger et al tested a subset of lung adenocarcinoma somatic mutations suspected as likely cancer drivers. We regarded a missense mutation as 'negative' for benchmarking if they were labeled 'neutral' by the expression-based method (eVIP) and did not appear as a hit in functional assays. We benchmarked these neutral mutations against two functional assays, an in vitro EGFR resistance and a xenograft tumorigenesis assay. The former is an erlotinib-rescue assay using PC9 cells treated at two erlotinib concentrations (300 nM and 3 µM), which we required resistance at both concentrations to be labeled a positive. The multiplexed xenograft tumorigenesis assay (TumorPlex) used pooled barcoded alleles to assess allele tumor formation capability by comparing barcode representation to pre-injection levels. We used the author defined threshold of a TumorPlex hit to label a mutation as a positive for benchmarking purposes.
TP53 transactivation from the IARC TP53 database
We assessed each methods ability to distinguish TP53 mutations with low transactivation (positive class) versus all other TP53 mutations (negative class). We evaluated all missense mutations (n=2,314) for TP53 from the IARC TP53 database 56 . Low transactivation was considered as less than 50% wildtype, as indicated by the median of 8 different targets (WAF1, MDM2, BAX, h1433s, AIP1, GADD45, NOXA, and P53R2).
Cell viability in vitro assay
We evaluated missense mutations (n=747) from a prior medium-throughput in vitro experiment on two growth-factor dependent cell lines, Ba/F3 and MCF10A
26
. We assessed each method's ability to distinguish mutations resulting in increased cell viability (labeled 'activating'; positive class) versus those that did not (labeled 'neutral'; negative class). The experiment assumes that mutations that provide a growth advantage to cells with growth factors withdrawn reflect cancer drivers. The study considered mutations as validated if the cell viability with the mutation was higher than wild type in either cell line (2 negative controls, 3 positive controls, and wild type).
Cancer type-specific benchmark
We evaluated how well methods could distinguish cancer type-specific driver genes based on a previously established benchmark 31 . Since the cancer type-specific benchmark measures performance by gene, we indicated a gene as a cancer driver if any missense mutation was found significant by CHASMplus. CHASMplus was executed on the same mutation data used for the other methods in the benchmark 13 . Class definitions were used as is from the authors.
Evaluation of performance was carried out by modifying the benchmarking scripts and data provided by the author to include CHASMplus (https://github.com/eduardporta/subgene_resolution).
Calculation of driver mutation frequency
Mutation frequency was calculated based on the fraction of cancer samples that contain a driver mutation in a particular cancer type. Estimates for pan-cancer analysis, which analyzes 32 cancer types, are based on the maximum frequency observed over each of the cancer types individually. The mutation frequency calculation uses the sum of driver mutations observed within the same codon, because the American College of Medical Genetics and Genomics (ACMG) guideline indicates other pathogenic mutations in the same codon provides moderate support for the pathogenicity of a mutation 57 . All mutations within a codon are then classified as rare (<1% of cancer samples), intermediate (1-5%), or common (>5%). As a result of certain cancer types having a low total number of cancer samples, we also regarded singleton mutations as rare.
Statistical power analysis
We estimated the statistical power to find frequently mutated codons within driver genes by using a binomial model, as done previously 43 . In contrast with gene-level estimates, the length in the model represents a codon ( ( =3 bases) and not a typical coding DNA sequence length Other parameters used to estimate statistical power were the same as done previously 43 .
Clustering of cancer types
We clustered TCGA cancer types according to two features, prevalence (fraction of mutated samples) and normalized diversity (normalized entropy) among predicted missense mutation drivers (q <= 0.01). The normalized entropy score was calculated based on the codon-level, as follows,
where there are k codons containing significant mutations, and the fraction of significant mutations in the i'th codon is p(i). We performed clustering using the k-means algorithm (scikit learn v0.18.0) where k, the number of clusters, was selected by the maximum silhouette score (k=5; varied between 2 and 10). Each parameterization was run ten times with different initial conditions to avoid local optimums by choosing the best run, defined as the lowest sum of distances to the closest centroid.
Subsampling procedure
We performed driver missense mutation predictions on random subsamples of each of 9
representative cancer types (ACC, SARC, PRAD, THYM, UVM, PAAD, BRCA, HNSC, and COAD), using CHASMplus. Subsampling was performed by randomly selecting a certain fraction of cancer samples without replacement. The designated fraction of samples for each iteration was randomly selected from a uniform distribution bounded between 0 and 1. We then ran CHASMplus using a 10-fold gene-holdout cross-validation model previously trained on the TCGA pan-cancer data. The number of unique driver missense mutations and overall driver prevalence (average number of driver missense mutations per cancer sample) were then calculated based on significant CHASMplus predictions (q<=0.01). The prevalence of a mutated residue within a particular sub-sampled result was measured against the full cohort.
